Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for Chemotherapy-induced Thrombocytopenia in Solid Tumors
NCT05218226Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Changes of the platelet counts after the treatment of Avatrombopag at 24 weeks. Started Feb 2022; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05218226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218226.